Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: A survey of 1,418 patients in Japan

American Journal of Geriatric Psychiatry

Volumn 16, Issue 7, 2008, Pages 584-593

  Uchida, Hiroyuki ^a,b   Suzuki, Takefumi ^a,d   Mamo, David C ^b,c   Mulsant, Benoit H ^b   Tanabe, Akira ^e   Inagaki, Ataru ^f   Watanabe, Koichiro ^g   Yagi, Gohei ^h   Tomita, Masayuki ⁱ  

^a Keio Medical School   (Japan)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Inokashira Hospital   (Japan)

^e NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^f KEIO UNIVERSITY   (Japan)

^g Ohizumi Hospital   (Japan)

^h Suisei Healing Center   (Japan)

ⁱ Asakadai Mental Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; BROMPERIDOL; CHLORPROMAZINE; CLOCAPRAMINE; CLOSPIPRAMINE; EMONAPRIDE; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; OXYPERTINE; PERICIAZINE; PEROSPIRONE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SULPIRIDE; SULTOPRIDE; THIORIDAZINE; TIMIPERONE; ZOTEPINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; DELUSIONAL DISORDER; DOSE CALCULATION; DRUG INDICATION; FEMALE; HEALTH SURVEY; HOSPITALIZATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MONOTHERAPY; ONSET AGE; PRESCRIPTION; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; UTILIZATION REVIEW; AGE; CLINICAL PRACTICE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; MIDDLE AGED; MULTICENTER STUDY; PSYCHOSIS; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; JAPAN; LINEAR MODELS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 50349095100     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e318172b42d     Document Type: Article

References (43)

1. Kane JM, Rifkin A, Woerner M, et al: Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates Arch Gen Psychiatry 1983; 40:893-896
2. Sim K, Su A, Leong JY, et al: High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. Pharmacopsychiatry 2004; 37:175-179
3. Leslie DL, Rosenheck RA: Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Med Care 2001; 39: 923-933
4. Jeste DV, Lacro JP, Gilbert PL, et al: Treatment of late-life schizophrenia with neuroleptics. Schizophr Bull 1993; 19:817-830
5. Mamo DC, Sweet RA, Chengappa KN, et al: The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders. Int J Geriatr Psychiatry 2002; 17:1012-1017
6. Herbert ME, Jacobson S: Late paraphrenia. Br J Psychiatry 1967; 113:461-469
7. Corey-Bloom J, Jernigan T, Archibald S, et al: Quantitative magnetic resonance imaging of the brain in late-life schizophrenia. Am J Psychiatry 1995; 152:447-449
8. Sato T, Bottlender R, Schroter A, et al: Psychopathology of early-onset versus late-onset schizophrenia revisited: an observation of 473 neuroleptic-naive patients before and after first-admission treatments. Schizophr Res 2004; 67:175-183
9. Pearlson GD, Kreger L, Rabins PV, et al: A chart review study of late-onset and early-onset schizophrenia. Am J Psychiatry 1989; 146:1568-1574
10. World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, WHO, 1992
11. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Ed, Washington, D.C., American Psychiatric Association, 1994
12. Jeste DV, Harris MJ, Krull A, et al: Clinical and neuropsychological characteristics of patients with late-onset schizophrenia. Am J Psychiatry 1995; 152:722-730
13. Rasmussen HB, Timm S, Wang AG, et al: Association between the CCR5 32-bp deletion allele and late onset of schizophrenia. Am J Psychiatry 2006; 163:507-511
14. Salzman C: Clinical Geriatric Psychopharmacology. Baltimore, Lippincott Williams&Willkins, 2005
15. Howard R, Rabins PV, Seeman MV, et al: Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. Am J Psychiatry 2000; 157:172-178
16. Howard RJ, Graham C, Sham P, et al: A controlled family study of late-onset non-affective psychosis (late paraphrenia). Br J Psychiatry 1997; 170:511-514
17. Barak Y, Aizenberg D, Mirecki I, et al: Very late-onset schizophrenia-like psychosis: clinical and imaging characteristics in comparison with elderly patients with schizophrenia. J Nerv Ment Dis 2002; 190:733-736
18. Jeste DV, Wetherell JL, Dolder CR: Schizophrenia and paranoid disorders, in The American Psychiatric Publishing textbook of geriatric psychiatry, Third Ed, Edited by Blazer DG, Steffens DC, Busse EW. Arlington, Va., American Psychiatric Association, 2004, pp 269-281
19. Arunpongpaisal S, Ahmed I, Aqeel N, et al: Antipsychotic drug treatment for elderly people with late-onset schizophrenia. Co-chrane Database Syst Rev 2003; CD004162
20. Inagaki A, Inada T, Fujii Y: Dose Equivalents of Psychotropic Drugs. Tokyo, Seiwa Press [Not available in English], 1999
21. Garfield P, Kent A, Paykel ES, et al: Outcome of postpartum disorders: a 10 year follow-up of hospital admissions. Acta Psy-chiatr Scand 2004; 109:434-439
22. Bauml J, Pitschel-Walz G, Volz A, et al: Psychoeducation in schizophrenia: 7-year follow-up concerning rehospitalization and days in hospital in the Munich Psychosis Information Project Study. J Clin Psychiatry 2007; 68:854-861
23. Lieberman JA, Perkins D, Belger A, et al: The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001; 50:884-897
24. Belitsky R, McGlashan TH: The manifestations of schizophrenia in late life: a dearth of data. Schizophr Bull 1993; 19:683-685
25. McGlashan TH: A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 1988; 14:515-542
26. Loranger AW: Sex difference in age at onset of schizophrenia. Arch Gen Psychiatry 1984; 41:157-161
27. Bellodi L, Morabito A, Macciardi F, et al: Analytic considerations about distribution of age of onset in schizophrenia. Neuropsy-chobiology 1982; 8:93-101
28. Steingard S, Allen M, Schooler NR: A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse. J Clin Psychiatry 1994; 55:470-472
29. Linden M, Scheel T, Xaver Eich F: Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study. Hum Psychopharma-col 2004; 19:111-119
30. Lipkovich I, Baron D, Houston J, et al: Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments. J Clin Psychopharmacol 2005; 25:381-386
31. Carpenter WT Jr, Kirkpatrick B: The heterogeneity of the long-term course of schizophrenia. Schizophr Bull 1988; 14:645-652
32. Harding CM, Brooks GW, Ashikaga T, et al: The Vermont longitudinal study of persons with severe mental illness, II: long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry 1987; 144:727-735
33. Aichhorn W, Weiss U, Marksteiner J, et al: Influence of age and gender on risperidone plasma concentrations. J Psychopharma-col 2005; 19:395-401
34. Moving G, Gustafson L, Franzen G, et al: Pharmacokinetics of remoxipride in elderly psychotic patients. Acta Psychiatr Scand 1990; 82(suppl 358):176-180
35. Kapetanovic IM, Sweeney DJ, Rapoport SI: Age effects on halo-peridol pharmacokinetics in male, Fischer-344 rats. J Pharmacol Exp Ther 1982; 221:434-438
36. Volkow ND, Wang GJ, Fowler JS, et al: Imaging endogenous dopamine competition with [HC]raclopride in the human brain. Synapse 1994; 16:255-262
37. Carlsson A, Winblad B: Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J Neural Transm 1976; 38:271-276
38. Wong DF, Pearlson GD, Tune LE, et al: Quantification of neuro-receptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. J Cereb Blood Flow Metab 1997; 17:331-342
39. Seeman P, Bzowej NH, Guan HC, et al: Human brain dopamine receptors in children and aging adults. Synapse 1987; 1:399-404
40. Rijcken CA, Monster TB, Brouwers JR, et al: Chlorpromazine equivalents versus defined daily doses: how to compare anti-psychotic drug doses? J Clin Psychopharmacol 2003; 23:657-659
41. Suzuki T, Uchida H, Tanaka KF, et al: Reducing the dose of antipsy-chotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. Int Clin Psychopharmacol 2003; 18:323-329
42. Uchida H, Suzuki T, Yamazawa R, et al: Reducing the dose of antipsychotic agents ameliorates visual hypersensitivity attack: an ideal treatment option in terms of the adverse effect. J Clin Psychopharmacol 2006; 26:50-55
43. Kawai N, Yamakawa Y, Baba A, et al: High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30:1009-1014